Categories
Report

(Nasdaq: MYMD) Profile

MyMD Pharmaceuticals, Inc. logo

OUR NEW PROFILE IS:   (NASDAQ: MYMD)

RA AFFECTS UP TO 14 MILLION PEOPLE AROUND THE WORLD

MYMD PHARMACEUTICALS PLANS FDA-CLEARED PHASE 2 CLINICAL TRIAL OF MYMD-1 IN RHEUMATOID ARTHRITIS

MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT POSITIVE TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY

VIEW THE INVESTOR PRESENTATION HERE

_______________________________

Hello Everyone, 

We have a brand new profile for today’s session that we want you to pull up immediately.

This one is sitting under .30 right now with major bounce potential.

Pull MYMD right away.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

MYMD PHARMACEUTICALS PLANS FDA-CLEARED PHASE 2 CLINICAL TRIAL OF MYMD-1 IN RHEUMATOID ARTHRITIS

DECEMBER 06, 2023 9:15AM EST

Company targets first quarter 2024 for trial initiation

Potential to be first orally-administered TNF-α inhibitor treatment for RA

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that its Investigational New Drug (IND) application for a Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA) was recently cleared by the U.S. Food and Drug Administration (FDA), and plans are underway for trial launch in the first quarter of 2024.

“With the FDA’s recent clearance of our IND in RA, we are moving forward with plans to initiate a Phase 2 trial within the next several months. Results from preclinical studies have demonstrated MYMD-1’s potential to treat RA, and we believe this drug could one day be a disruptor in the massive market for similar treatments,” said Chris Chapman, M.D., president, director, and chief medical officer of MyMD.

Differentiated by its ease of oral dosing and selectivity, MYMD-1 is a TNF-α inhibitor with a small molecule design that enables the drug to cross the blood brain barrier for entry into the central nervous system. In a preclinical trial, MYMD-1 was shown to significantly reduce swelling and other clinical arthritis measures compared to widely used RA therapy Enbrel® (etanercept).1 Disease severity (total composite score) was reduced by 47% with MYMD-1 (450 mg/kg/day orally) versus a 37% reduction with etanercept (10 mg/kg by subcutaneous injection).

Under this IND, the Phase 2 clinical trial of MYMD-1 will be a randomized placebo-controlled study that is expected to enroll approximately 60 patients with active rheumatoid arthritis. Patients will receive oral MYMD-1 dosing of 1050 mg.

Market Opportunity

Rheumatoid arthritis is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints and affects approximately 1.5 million Americans. RA’s cost to society, including healthcare costs; loss of employment; costs to employers, government, and caregivers; and costs associated with a deterioration of quality of life, is estimated to be over $40 billion annually.2

About MYMD-1

Originally developed for autoimmune diseases, MYMD-1’s primary purpose is to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan. Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. Its mechanism of action and efficacy in diseases including multiple sclerosis (MS) and thyroiditis have been studied through collaborations with several academic institutions.

MYMD-1 has shown effectiveness in preclinical and clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these studies to selectively block TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation.

MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT POSITIVE TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY

JULY 31, 2023 9:00AM EDT

– MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment

– MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α(P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03)

– First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets

– Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced statistically significant positive topline results from its randomized Phase 2 study of oral TNF-α inhibitor, MYMD-1® in patients with chronic inflammation associated with sarcopenia, or age-related frailty. The study met its primary endpoints of significantly reducing chronic inflammatory markers in participants treated with MYMD-1. MYMD-1 has the potential to be the first drug approved by the United States Food and Drug Administration (FDA) for sarcopenia, an age-related decline in physical function which leads to greater risk of hospitalization, disability, and death.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230731983609/en/

The study met both of its primary endpoints, significantly reducing serum levels of three biomarkers, TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) and maintaining appropriate plasma concentrations and parameters in pharmacokinetic evaluations. The study also achieved all secondary endpoints related to safety and tolerability. There were no treatment-related adverse events (AEs) or serious adverse events (SAEs) over the course of the study.

“We are very excited about these results indicating MYMD-1 demonstrated statistically significant reductions in all three inflammatory markers and met all additional pharmacokinetic and safety endpoints needed to advance our sarcopenia clinical program, with guidance from the FDA,” said Chris Chapman, M.D., President, Director, and Chief Medical Officer at MyMD. “These results support the unique advantages of MYMD-1 as the first oral, selective TNF-α inhibitor candidate and potential future treatment option for sarcopenia and other autoimmune conditions such as rheumatoid arthritis.”

The Phase 2 multi-center double-blind, placebo controlled, randomized study (NCT05283486) was designed to investigate the efficacy, tolerability and pharmacokinetics of MYMD-1 in participants aged 65 years or older with chronic inflammation associated with sarcopenia/frailty, a condition linked to elevated levels of proinflammatory cytokines. Patients in the study were dosed weekly with MYMD-1 or placebo over a 28-day period. The study consisted of four dosing cohorts versus placebo (600mg, 750mg, 900mg and 1050mg).

“We are encouraged by the reduction of inflammatory markers along with the favorable safety profile demonstrated in this study of an oral TNF-α inhibitor,” continued Dr. Chapman. “Sarcopenia can significantly affect people as they age, and there are currently no approved treatments for the condition. A selective, oral treatment that reduces TNF-α and inflammation and does not require infusion or injection would be a welcome advance for this population.”

Full results from the study will be presented or published at a later date to be determined. The company plans to initiate discussions with the FDA regarding a Phase 3 study of MYMD-1 in sarcopenia.

NEWS

DEC 06, 2023 9:15AM EST

MYMD PHARMACEUTICALS PLANS FDA-CLEARED PHASE 2 CLINICAL TRIAL OF MYMD-1 IN RHEUMATOID ARTHRITIS 

OCT 04, 2023 7:30AM EDT

MYMD PHARMACEUTICALS TO PRESENT UPDATED STATISTICALLY SIGNIFICANT PHASE 2 DATA FOR MYMD-1, POTENTIAL TNF-Α MARKET DISRUPTER, AT BIOFUTURE 2023 

AUG 14, 2023 8:30AM EDT

FDA ACCEPTS MYMD PHARMACEUTICALS’ INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR PHASE 2 STUDY OF ORAL TNF-Α INHIBITOR MYMD-1® IN RHEUMATOID ARTHRITIS (RA) 

AUG 02, 2023 8:30AM EDT

MYMD PHARMACEUTICALS TO HOLD CONFERENCE CALL TODAY TO DISCUSS PHASE 2 TRIAL RESULTS 

JUL 31, 2023 9:00AM EDT

MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT POSITIVE TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY 

APR 12, 2023 8:30AM EDT

MYMD PHARMACEUTICALS® PROVIDES DOSING UPDATE ON PHASE 2 MULTI-CENTER CLINICAL TRIAL OF MYMD-1® AS A THERAPY FOR DELAYING AGING AND EXTENDING HEALTHY LIFESPAN 

MAR 20, 2023 8:55AM EDT

MYMD PHARMACEUTICALS® AND CHARLES RIVER PRESENT POSITIVE DATA FOR NEXT GENERATION, ORAL TNF-Α INHIBITOR MYMD-1® IN RHEUMATOID ARTHRITIS 

MAR 08, 2023 8:30AM EST

MYMD JOINS LOT NETWORK IN EFFORT TO PROTECT COMPANY AND SHAREHOLDERS FROM PATENT TROLLS 

MAR 02, 2023 8:30AM EST

MYMD ANNOUNCES U.S. DRUG ENFORCEMENT ADMINISTRATION (DEA) DETERMINES SUPERA-CBD™ IS NOT A CONTROLLED SUBSTANCE OR LISTED CHEMICAL 

FEB 28, 2023 8:30AM EST

MYMD PHARMACEUTICALS® ANNOUNCES UPCOMING PRESENTATION OF PRECLINICAL RHEUMATOID ARTHRITIS DATA FOR ORAL TNF-Α INHIBITOR MYMD-1® AT THE SOCIETY OF TOXICOLOGY 2023 ANNUAL MEETING

MANAGEMENT TEAM

Chris Chapman, M.D.

CHRIS CHAPMAN, M.D.

President, Chief Medical Officer and Director

Chris Chapman, M.D., was appointed as President and Chief Medical Officer of MYMD Florida effective as of November 1, 2020. Prior to joining MYMD Florida and since 1999, Dr. Chapman has also served as the Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., a consulting organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. In addition, from 2003-2004, Dr. Chapman served as the Associate Director of Drug Safety, Pharmacovigilance, and Clinical Operations for Organon Pharmaceuticals, where he was responsible for the supervision of four fellow M.D.s and 10 drug safety specialists. Prior to his time at Organon, Dr. Chapman served as Director, Medical Affairs, Drug Safety and Medical Writing Departments at Quintiles (currently known as IQVIA), from 1995-2003, where he grew the division from no employees to forty employees, including eight board certified physicians, four RNs, two pharmacists, eight medical writers and supporting staff. Dr. Chapman has also served on the board of directors of Rock Creek Pharmaceuticals, Inc. (f/k/a Star Scientific, Inc.) from 2007-2016, including as a member of the Audit Committee from 2007-2014, chairperson of the Compensation Committee from 2007-2014, and chairperson of the Executive Search Committee from 2007 to 2014. Dr. Chapman is an experienced executive and global medical expert and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult and pediatric subjects. Dr. Chapman is also the founder of the Chapman Pharmaceutical Health Foundation, an IRS Section 501(c)(3) nonprofit organization established to solicit public funds and to support healthcare needs such as AIDS, diabetes, hypertension, lupus, sickle cell anemia, malaria and tuberculosis, which was organized in 2006. Dr. Chapman is a graduate of the Harvard Kennedy School of Cambridge, Massachusetts for financial management in 2020. Dr. Chapman received his M.D. degree from Georgetown University in Washington, D.C. in 1987, and completed his internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular and Obstetric Anesthesiology at Georgetown.

Adam Kaplin, M.D., Ph.D.

ADAM KAPLIN, M.D., PH.D.

Chief Scientific Officer

Adam Kaplin, M.D., Ph.D., was appointed Chief Scientific Officer of MYMD Florida effective as of December 18, 2020. Prior to joining MYMD Florida, Dr. Kaplin has served in a number of positions at John Hopkins University, including Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine, positions he has held at various times from 2002 to present. In addition, since 2019, Dr. Kaplin has served as Adjunct Faculty at the George Mason University Department of Global and Community Health. Dr. Kaplin has also served as Co-Founder of numerous healthcare related startups, including, from 2018 to present, REWARD Pathways Inc., a company devoted to addiction treatment development focused on a combined eHealth and medicine approach to curing addiction, and from 2016 to present, Hollinger Kaplin Benjamin & Bond, an eHealth software development company. Dr. Kaplin’s research focuses on the investigation of the biological basis of immune mediated depression and cognitive impairment by using multiple sclerosis as the model. Dr. Kaplin has also been active for over a decade in the development and application of health information technology to mental health, combining this work with providing neuropsychiatric consultation and ongoing care of patients with multiple sclerosis spectrum disorders. Dr. Kaplin’s original research has been published over 40 times in several different publications, and he has authored or co-authored numerous review articles and textbooks. Dr. Kaplin received his B.S. in Biology from Yale University, graduating cum laude in 1988, and received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine in 1996.

Paul Rivard, Esq.

PAUL RIVARD, ESQ.

Executive Vice President of Operations and General Counsel

Paul Rivard, Esq., was appointed Executive Vice President of Operations and General Counsel of MYMD Florida effective as of September 21, 2020. Prior to joining MYMD Florida, Mr. Rivard was a principal shareholder of Banner Witcoff, a national law firm specializing in intellectual property law, from 2003-2020, and in that capacity also served as Chair of the firm’s Prosecution Policies and Procedures Committee, developing and refining internal procedures, workflow, and docketing practices to improve efficiencies and mitigate risk. Before becoming a principal shareholder, Mr. Rivard was an associate at Banner Witcoff from 1998-2002. In addition, prior to his time at Banner Witcoff, Mr. Rivard served as a patent examiner for the United States Patent and Trademark Office from 1992-1998. Mr. Rivard brings more than 20 years of experience as intellectual property counsel for clients ranging from startups to Fortune 100 companies in the life sciences, chemical and consumer product industries, including primary outside intellectual property counsel for MYMD Florida from 2014-2020. Mr. Rivard has worked closely with strategic decision makers and in-house counsel of his numerous clients, seeking to align intellectual property procurement, enforcement and licensing strategies with business objectives. Mr. Rivard received his Juris Doctor from Catholic University of America’s Columbus School of Law, graduating cum laude in 1998, and his B.S. in Chemical Engineering from Clarkson University in 1992.

IAN RHODES

Chief Financial Officer

Ian Rhodes was appointed as Interim Chief Financial Officer on February 1, 2021. Mr. Rhodes joined Brio Financial Group (“Brio”) in January 2021. From March 2020 to December 2020, Mr. Rhodes served as the Interim CFO of Roadway Moving and Storage. From November 2018 to July 2019, he served as Interim CFO of Greyston Bakery and Foundation. From December 2016 to September 2018, Mr. Rhodes served as President, CEO and Director of GlyEco, Inc., and served as CFO of GlyEco, Inc. from February 2016 to December 2016. From May 2014 to January 2016, he served as CFO of Calmare Therapeutics. Mr. Rhodes began his career at PricewaterhouseCoopers, where he worked for 15 years. Mr. Rhodes holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall University and is a licensed CPA in New York.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY MYMD AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Categories
Report

(Nasdaq: BRSH) Profile

Brüush acquires The Dollar Brush as it gears up for expansion (CNW Group/Bruush Oral Care Inc.)

OUR NEW PROFILE IS:   (NASDAQ: BRSH)

BREAKING NEWS ON FRIDAY:  BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER

BRUUSH IS ENDORSED BY FAMOUS COMEDIAN KEVIN HART

THEY  HAVE RECEIVED OVER 3,000 ORGANIC REVIEWS WITH A 90% 5-STAR RATING

THEIR RETURN RATE IS LESS THAN 1%, COMPARED TO A U.S. NATIONAL AVERAGE RETURN RATE OF 21% FOR ONLINE PURCHASES

THEIR ANNUAL CHURN RATE ON ACTIVE SUBSCRIPTIONS IS ONLY 12%, WHEREAS DOLLAR SHAVE CLUB AND HARRY’S BOTH HAVE AN ANNUAL CHURN RATE OF ALMOST 70%

VIEW THE INVESTOR PRESENTATION HERE

_______________________________

Hello Everyone,

We wanted to alert you to another exciting profile for Monday’s session.

This one had some incredible merger news on Friday and went viral, closing up 17%, after being up over 100% on the session.

BRSH has developed its sonic-powered Bruush electric toothbrush to make upgrading to an electric brush appealing.

Did you know that when you brush manually, you average only 200 brush strokes a minute while our Brüush provides up to 42,000 sonic vibrations per minute? That’s over 200x more than your manual!

This is a game-changing electric toothbrush that is attracting many subscribers already.

There are now over 38,000 active subscriptions in its brush head refill program and the Company’s internal research demonstrated that over 85% of subscribers are interested in adding Consumables to their existing subscriptions.

Electric toothbrushes are superior to manual, but the majority of people have not switched

  • Studies have shown that electric toothbrushes are more effective than manual toothbrushes1
  • Despite clear oral care benefits, most people still use a traditional manual toothbrush2
  • The low adoption rate shows that consumers do not find the current electric toothbrush value proposition compelling

  • They  have received over 3,000 organic reviews with a 90% 5-star rating
  • Their return rate is less than 1%, compared to a U.S. national average return rate of 21% for online purchases
  • Their annual churn rate on active subscriptions is only 12%, whereas Dollar Shave Club and Harry’s both have an annual churn rate of almost 70%

BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER

VANCOUVER, BC and INDIANAPOLIS, IN / ACCESSWIRE / December 15, 2023 / Bruush Oral Care Inc.(Nasdaq:BRSH) (“Brüush”) and Arrive Technology Inc. (“Arrive”), a technology company focused on facilitating the last inch of the last-mile for autonomous delivery, today announced they have entered into an agreement and plan of merger. The combined company (“Combined Company”) will focus on the advancement and implementation of Arrive’s smart Mailbox-as-a-Service (MaaS) platform that makes the exchange of goods between people, robots and drones frictionless through the use of artificial intelligence (“AI”). The Combined Company is expected to operate under the name Arrive Technology Inc. with its shares listed on the Nasdaq Capital Market under the ticker symbol ‘ARRV’.  

“We are thrilled to announce this proposed merger with Arrive,” remarked Aneil Manhas, Chief Executive Officer of Brüush. “In a world hungry for a future of automated last-mile delivery, there is a critical need for a smart and secure exchange point, which Arrive is poised to redefine with its smart mailbox technology. Arrive’s strong management team, robust IP portfolio and unique Mailbox-as-a-Service platform that integrates artificial intelligence (AI) and machine-learning capabilities, positions the company well to sit at the center of the autonomous delivery network in the evolving landscape of automated exchanges. We reviewed and evaluated numerous strategic alternatives for creating stockholder value and believe this transaction with Arrive presented the most compelling option for our shareholders.”

Arrive’s Chief Executive Officer Dan O’Toole said: “We are excited about becoming Indiana’s 42nd publicly listed company and are confident our AI-powered MaaS platform will deliver excellent value to existing shareholders of both Arrive and Brüush, as well as new shareholders. This agreement and plan of merger will accelerate the development and deployment of our third-generation smart mailbox and continue to support the autonomous delivery revolution.”

About the Transaction, Management and Organization

Under the terms of the merger agreement, Brüush and Arrive will conduct a business combination in the form of a reverse triangular merger (“Merger”) via an all-stock transaction. Brüush (“PubCo”) through its wholly owned subsidiary (“Merger Sub”) will merge with and into Arrive (“Target Company“) with Target Company continuing under the name of Arrive Technology Inc. and as a wholly owned subsidiary of PubCo.

Upon completion of the Merger, the outstanding shares of Target Company’s common stock, will be exchanged for common shares of PubCo representing upon issuance, 94.5% of PubCo’s issued and outstanding common shares on a fully diluted basis. The legacy shareholders of PubCo will own shares of PubCo common shares representing 5.5% of PubCo’s issued and outstanding common shares on a fully diluted basis. The merger has been approved by the board of directors of both companies and is expected to close in the first quarter of 2024, subject to customary closing conditions.

Prior to closing, PubCo will, among other things, effect a reverse stock split with respect to PubCo’scommon shares at a ratio within the range of 6-for-1 to 200-for-1. Additionally, PubCo, will maintain a net cash minimum of US$10,000,000 consisting of cash and cash equivalents after full payment of current liabilities, including any financing and expenses in connection with the Merger. After the closing of the Merger, PubCo will sell, transfer and assign all existing legacy business, assets and liabilities of PubCo to a purchaser and pursuant to that certain separation and distribution agreement to be entered into by and between PubCo and such purchaser on terms and conditions to be mutually agreed by PubCo and such purchaser.

Additional information and details about the transaction will be provided in a Form 6-K which will be filed by Brüush with the Securities and Exchange Commission (“SEC”) and will be available at www.sec.gov.

The Combined Company will focus on advancing Arrive’s existing operations as a technology company with a focus on designing and implementing a Mailbox-as-a-Service platform that facilitates smart, secure and seamless exchange of packages between people, robots and drones. Arrive’s patented smart mailbox system leverages climate-assisted cargo space, smart alerts and advanced chain of custody controls to secure the last inch of the last-mile for all shippers, delivery services and autonomous delivery networks. Arrive’s solutions are critically and uniquely positioned in the supply chain to leverage its unique data assets for artificial intelligence to provide users with machine-learning based insights that can aid businesses and consumers to lower logistical costs and capture new growth opportunities, among other benefits.

Following the consummation of the Merger, the Combined Company will be headquartered in Indianapolis, Indiana and it is anticipated that the Combined Company will be led by current members of the Arrive management team, including:

●Dan O’Toole, Chief Executive Officer
●Todd Pepmeier, Chief Financial Officer
●Mark Hamm, Chief Operations Officer
●Torrey Bievenour, Chief Technology Officer
●Neerav Shah, Chief Strategy Officer
●Lora O’Toole, Vice President Business Development
●John Ritchison, Corporate Counsel

The Board of Directors of the Combined Company is expected to consist of five members, one of which will be designated by Brüush and the remainder will be designated by Arrive.

Over the last ten years, subscription companies have become all the rage. These are the companies that send you packages regularly consisting of items you have picked out or they have picked out for you.

BRSH CEO Aneil Manhas believes that the company has done an excellent job of creating a premium product for an affordable price. When you get your Brüush toothbrush, you can immediately tell it is a premium product.

Toothbrush heads should be replaced every 12 weeks — which makes BRSH’s subscription model that sends customers three new brush heads every six months (for about $22) a convenient way to stay on top of changing them.

They’ve grown considerably in popularity due to their convenience. Products range from foods and beverages to household goods, clothing, beauty, books, and more. There’s a subscription for almost everything.

Subscription businesses grew revenues about 5 times faster than S&P 500 company revenues (18.2% versus 3.6%), and U.S. retail sales (14.9% versus 2.3%) from 2012 to 2020.

$600 billion by 2026! How is BRSH aiming to take a piece of this market?

The rapidly growing, direct-to-consumer leader offers subscription-based, aesthetically pleasing electric toothbrushes and oral care products.

The company has a goal to become the go-to oral care brand for millennials and Generation Z, two substantial markets.

How big are these two markets?

Nearly half of Gen Z’ers (46%) and millennials (49%), for instance, were interested in subscriptions on average, compared with about a third (34%) of the general public. 4.7

As you can see with this striking revenue growth disparity, the transformative impact of the subscription model on modern business practice is huge. Looking ahead, the subscription economy is forecast to be worth.

Endorsed by Kevin Hart….

The Bruush toothbrush is a favorite of comedian and actor Kevin Hart who signed up to be company ambassador!

“Together, we are going to take Brüush to the next level of growth and break some of the norms of the category while we are at it.”

– Kevin Hart

NEWS

PUBLISHED

1 DAY AGO

BRUUSH ORAL CARE INC. AND ARRIVE TECHNOLOGY INC. ANNOUNCE AGREEMENT AND PLAN OF MERGER

PUBLISHED

NOV 17, 2023

BRÜUSH RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID REQUIREMENTS

PUBLISHED

OCT 5, 2023

BRÜUSH ANNOUNCES NOTICE FROM NASDAQ FOR CONTINUED LISTING

PUBLISHED

OCT 2, 2023

BRÜUSH ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT

PUBLISHED

JUL 31, 2023

BRÜUSH ORAL CARE INC. ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT EFFECTIVE PRE-MARKET OPENING ON AUGUST 1, 2023

PUBLISHED

JUL 26, 2023

BRÜUSH ORAL CARE INC. ANNOUNCES RECEIPT OF NOTICE FROM NASDAQ REGARDING THE DETERMINATION OF DELISTING

PUBLISHED

MAY 31, 2023

BRÜUSH TO PRESENT AT THE GRAVITAS 4TH LOS ANGELES SUMMIT

PUBLISHED

APR 18, 2023

BRÜUSH TO PRESENT AT THE SEQUIRE INVESTOR SUMMIT IN PUERTO RICO

PUBLISHED

APR 4, 2023

BRÜUSH APPOINTS NEW CHIEF FINANCIAL OFFICER

PUBLISHED

MAR 22, 2023

BRÜUSH TO CONTINUE TO DISRUPT AT-HOME ORAL CARE WITH UPCOMING NEW PRODUCTS

PUBLISHED

MAR 2, 2023

PARVIS INVEST INC. AND GRAVITAS II CAPITAL CORP. RECEIVE CONDITIONAL APPROVAL OF REVERSE TAKEOVER TRANSACTION AND FILE FILING STATEMENT

PUBLISHED

FEB 28, 2023

BRÜUSH TO PRESENT AT THE GRAVITAS 6TH ANNUAL GROWTH CONFERENCE

MANAGEMENT TEAM

Aneil Manhas, Chief Executive Officer

Aneil Manhas, the founder of the Company, has served as Chief Executive Officer since inception. Mr. Manhas has a career spanning over 15 years working in the financial services industry and in CEO positions of his previous companies

Recently, he was CEO of Surface 604, an electric bike company that he founded in 2015 and grew to be one of North America’s leading e-bike brands. He was also President and CEO of GVA Brands / Rosso Sports, a company he purchased in 2014 and transformed into Canada’s leader in entry-level powersports.

Mr. Manhas previously worked at Credit Suisse in Los Angeles, California for two years as an Investment Banking Analyst before joining Onex Corporation in Toronto, Ontario as a member of the investment team for five years, evaluating and executing large private equity transactions across multiple industries.

Aneil holds an Honours Business Administration (HBA) from the Richard Ivey School of Business at the University of Western Ontario.

Mandeek Manhas, Chief Financial Officer

Mandeek Manhas joined the Company in April 2023 as Chief Financial Officer to direct and oversee the Company’s finance department. Mr. Manhas has over 17 years of experience in a variety of leadership, managerial, financial, accounting, regulatory compliance, assurance, tax and advisory areas. This includes leading initiatives over operational and financial strategy, assessment of growth opportunities, governance and risk management.

Mr. Manhas joins the Company from Shape Properties, a real estate management, development and investment company with over $2.5 billion in asset value under management. As Director of Finance and Accounting for the income producing properties group, he led the finance and accounting functions through budgeting and forecasting, cash management, financial reporting, tax compliance, commercial support and overall growth of the portfolio of assets under management.

Previously, Mr. Manhas was Corporate Controller at Jervois Global (ASX: JRV, TSX-V: JRV), a dual-listed, multinational mining company with advanced development stage and exploration projects, where he led the finance department through a three-way merger with Ecobalt Solutions Inc. (TSX: ECS) and M2 Cobalt Corp. (TSX-V: MC). Prior to this, Mr. Manhas spent eleven years providing audit and advisory services with major accounting firms including Deloitte, Grant Thornton and Crowe MacKay, primarily working with small to mid-market cap corporations listed on Canadian and US exchanges.

Mr. Manhas is a Chartered Professional Accountant and holds a Bachelor of Commerce Degree from the University of British Columbia, with a double major in Finance and Accounting.

Alan MacNevin, Chief Operating Officer

Alan MacNevin joined the Company in June 2022 as Chief Operating Officer and leads the Company across all aspects of operations, driving strategic growth by directing and overseeing the scale of digital commerce, execution of strategic partnerships, launch of new products and expansion into new geographical markets. Mr. MacNevin has over 20 years of experience in executive-level positions managing large teams globally, while leading the growth at start-up e-commerce and subscription-based businesses and building them into category leaders.

Mr. MacNevin joins the Company from Rakuten Kobo, where over the past ten years he has held various executive positions including Chief Revenue Officer (2014-2015), Chief Marketing Officer (2015-2019), and most recently, Chief Operating Officer (2019-2022), where he managed the day-to-day global operations of the company. Driving growth, profitability and international expansion, Mr. MacNevin played a key role in Kobo’s emergence as a dominant player in the eReading industry.

Prior to joining Rakuten Kobo, Mr. MacNevin was a member of the executive team at Sirius Satellite Radio for six years from 2005 to 2011.  At Sirius, Mr. MacNevin led the subscriber management team as the company grew from inception to over two million subscribers before it merged with XM Canada in 2011.  Mr. MacNevin has also held senior marketing and operational roles at the Canadian Broadcasting Company, Chapters-Indigo Online and Bell Mobility.

SINCERELY,

DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIFTEEN THOUSAND USD BY AMPLIFYIR INC FOR A ONE DAY BRSH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Categories
Report

(Nasdaq: MGRX) Profile

Mangoceuticals, Inc. logo

OUR NEW PROFILE IS:   (NASDAQ: MGRX)

52% OF MEN EXPERIENCE SOME FORM OF ERECTILE DYSFUNCTION THROUGHOUT THEIR LIFE AND THAT TOTAL INCREASES ANYWHERE FROM 5-15% BETWEEN AGES 40 AND 70

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

MGRX EXPERIENCED SEQUENTIAL REVENUE GROWTH OF 28.8% FROM Q1 TO Q2, 42.5% FROM Q2 TO Q3, AND 59% FROM Q1 TO Q3

SUBSCRIPTION SALES INCREASED 65% FROM Q1 TO Q3, WITH Q2 TO Q3 SEQUENTIAL GROWTH OF 47%

MANGOCEUTICALS, INC.’S DEBUT COMMERCIAL SURPASSES 9.3 MILLION VIEWS ON YOUTUBE

*****BREAKING NEWS RELEASED THIS MORNING*****

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

THE DALLAS BASED, DIRECT-TO-CONSUMER TELEMEDICINE COMPANY SECURES MARKETING AGREEMENT WITH MARIUS PHARMACEUTICALS BRINGING KYZATREX TO THE TELEHEALTH MARKET AS ‘PRIME’ BY MANGORX

Dallas, Texas & Raleigh, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it has entered into a Marketing Agreement with Marius Pharmaceuticals(“Marius”) to market and sell KYZATREX®️, an innovative FDA-approved oral Testosterone Replacement Therapy (TRT) product, under the program, ‘PRIME’ by MangoRx.

PRIME will be available on MangoRx’s telemedicine platform with an anticipated launch date of January 31, 2024.

KYZATREX, a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions, is one of only three FDA approved TRT treatments that is delivered orally–as opposed to the traditional, invasive, and inconvenient injection-based drug delivery protocol. KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Testosterone deficiency is often first recognized through symptoms of fatigue or low energy, decreased sex drive, lower muscle mass and many other negative downstream impacts. PRIME, powered by KYZATREX, can help men restore Testosterone to normal levels and improve how they feel. In a 6-month open-label clinical study of 139 hypogonadal patients, 88% of patients taking KYZATREX had normal testosterone levels at Day 90 (worst case scenario (WCS) efficacy calculation, excluding Site 104).1 Among study completers (n=127), 96% of KYZATREX patients achieved normal testosterone levels at Day 90.2 With PRIME, MangoRx will expand broad-based consumer access to this innovative therapy.

TRT treatments have traditionally been delivered through intramuscular needle injection, a subcutaneous implant, or a topical gel. These applications have suffered from different drawbacks depending on the delivery method, such as painful administration, uneven absorption, risk of transfer to others, and disruptions to the body’s natural diurnal rhythm allowing for peak performance early in the day.

Twice daily oral TRTs offer painless administration, promote steady absorption, lower SHGB levels, increase free T levels to give the body more usable testosterone, and work with the body’s natural diurnal rhythm. Oral softgels are also convenient, mess-free, and discreet.

Shalin Shah, CEO of Marius, shared, “This expansion into telehealth marks an important step in the care of Testosterone Deficient patients. Testosterone Deficiency is a serious chronic disease and has been inadequately addressed by previous generations of products. KYZATREX marks a shift in the treatment paradigm and a meaningful opportunity for patients seeking to restore optimal testosterone levels. Marius is excited to partner with MangoRx as an innovative partner in the DTC marketplace. We look forward to the Mango team bringing more awareness around the significance of Testosterone as a metabolic hormone and its role in optimal health for men with Low T.”

PRIME by MangoRx will bring KYZATREX to patients spanning 48 states through the Company’s telemedicine platform, which is optimized to deliver a smooth medical prescription process, including blood work and synchronous telehealth visits with a fully licensed prescribing physician. Orders will be reviewed and, pending approval, fulfilled, then discreetly shipped via MangoRx’s URAC accredited mail order partner pharmacy directly to the patient’s doorstep.

Jacob Cohen, MangoRx’s Co-Founder and CEO, noted, “PRIME represents a critical expansion into a new vertical with massive market potential and very little competition on the consumer side, while remaining completely consistent with our established identity as a company committed to providing new and innovative pharmaceutical based solutions helping men achieve optimal performance in all areas of life. We are extremely fortunate to be working with Marius and to be one of only a few companies with access to this innovative product. With our established marketing and telemedicine infrastructure in place, we are ready to hit the ground running and take PRIME to patients in need across the country next month.”

Testosterone deficiency affects approximately four in ten men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society.3,4 Between 10% and 40% of men worldwide suffer from low testosterone levels.5

_____________________

Hello Everyone,

We saw a slew of double digit winners in November that we profiled here on the newsletter.  It was a tremendous month for us here on our newsletter.  If you have been following then you already know.

We have a new profile for tomorrow that we want you to research right away.

Pull up MGRX immediately.

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”).

Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

Mangoceuticals is making waves in the men’s health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers.

The men’s health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men’s health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector.

The men’s health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men’s health, including physical fitness, mental wellness, and nutritional support.

Beyond product offerings, Mangoceuticals understands the importance of education and information in men’s health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men’s health.

MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men’s health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep.

The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of ‘intimate well-being’ is an enjoyable experience.

Mango (Man-Go)

Mango, Mangoceuticals’ flagship product, is a groundbreaking solution designed to address men’s unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.

Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED.

Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men’s health and wellness products to new potential customers.

Mango is now available in 44 states, including Nevada and the District of Columbia.

MANGOCEUTICALS, INC. PROVIDES UPDATE TO SHAREHOLDERS ON Q3 ACHIEVEMENTS AND GUIDANCE ON YEAR END AND NEAR-TERM INITIATIVE

Dallas, Texas, Oct. 19, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to provide the following updates to current and prospective shareholders on the Company’s recent 3rd quarter achievements, along with guidance on year end and near-term initiatives. MangoRx is pleased to report on the following topics:

Year to Date Company Achievements (through September 30, 2023)

  • Revenue Growth: The Company experienced sequential revenue growth of 28.8% from Q1 to Q2, 42.5% from Q2 to Q3, and 59% from Q1 to Q3. We attribute this growth to three primary factors: 1) the growing prominence of the Mango brand, 2) the Company’s aggressive marketing efforts through digital initiatives as well as sponsorships and promotions with Barstool Sports and the various podcast platforms launched with Audacy (as referenced in our press release dated September 6, 2023), and 3) funds raised in our initial public offering.
  • Customer Acquisition: To date, we have successfully onboarded a rapidly growing customer base with an Average Order Value (AOV) of $105. Our goal is to continuously increase our customer base through additional prospecting and retargeting efforts. We have also launched an aggressive email marketing campaign to reach out to customer leads that have expressed interest in our products. To date, we have received positive results and plan to continue these efforts on an ongoing basis.
  • Customer Subscriptions and Refills: Historically, subscribing customers have accounted for approximately 10% of all new orders with an Average Order Value (AOV) of approximately $130. Subscription sales increased 65% from Q1 to Q3, with Q2 to Q3 sequential growth of 47%, demonstrating an accelerating growth curve.

Additionally, many of our subscribing customers manually refill additional orders prior to receiving their scheduled auto-refill prescriptions, which we believe reflects the strong value-add role our Mango ED products have for our customers. Our goal is to grow the share of new orders that come from subscribing customers from 10% to 20-25%, which if successful, we expect will drive greater predictability and growth in revenues and cash flow, allowing the Company to invest even more aggressively in new customer acquisition.

  • New Orders and Refills: For the nine-months ending September 30, 2023, new orders accounted for 76% of total revenues while refills/auto-refills accounted for 24% of total revenues. Sales from refills/auto-refills have grown sequentially by more than 50% over the past two consecutive quarters.

4th Quarter Goals and Initiatives

  • New Men’s Health Product Categories: The Company has developed, and is in the process of developing, new men’s health and wellness pharmaceutical grade products expected to be launched and marketed and made available on www.MangoRx.com through our telemedicine portal. These product categories include, but are not limited to: hair loss, weight loss, performance, and various hormone therapies.

The Company has been working with internal product developers, third-party software developers, packaging vendors, marketing agencies, doctors’ networks, and the Company’s related-party compounding pharmacy, to ensure the timely and successful launch of these new and innovative products. The Company anticipates launching at least one additional product category by the end of the 4th quarter or the first quarter of 2024, funding permitted.

  • New Web Design and User Experience: The Company has undertaken a complete redesign of its website, www.MangoRx.com. Currently, the Company’s website is singularly geared toward its erectile dysfunction Mango products. As the Company expands into new product categories, a newer design and user interface experience is necessary for the promotion and marketing of those new products. The Company anticipates launching its new web presence by the end of the 4th quarter.
  • Launch of Affiliate Marketing Program: The Company is extremely pleased with the launch of its Affiliate Marketing Program, which allows various companies, influencers, and publishers to market and sell MangoRx products as an affiliate. Interested parties can sign up to become an affiliate at www.MangoRevenue.com, where they will have access to Company approved media, tools, and content to use on their own marketing platforms. If a purchase is made using their unique link or code, these affiliates are paid a commission on each product sold. Since launching the program in early October 2023, the Company has already signed up 100 affiliates in short order and has a goal of achieving 500 affiliates by the end of 2023.

The Company estimates that a well-executed and managed affiliate marketing program may be able to drive up to 20% of the Company’s overall gross revenues.

  • Ongoing Marketing Initiatives: The Company has recently retained digital marketing agency Accelerated Digital Media (ADM), a digital media and marketing agency that specifically focuses on direct-to-consumer telemedicine and pharmaceutical brands. With clients including NURX, TalkSpace, and Keeps, management believes that the ADM team has the skills necessary to launch and execute an effective digital marketing strategy to assist with our social media advertising on top-of-funnel ad platforms such as Meta (Instagram/Facebook), Google, and YouTube.

All of this is in addition to the Company’s current sponsorships of various nationally recognized podcasts such as NoJumper and PlugTalk with Adam22, Pillow Talk with Ryan Pownall, OnlyStansby BarStool Sports and Glenny Balls, Monday Morning Podcast with Bill Burr, Fly on the Wall with Dana Carvey and David Spade, The Dale Jr Podcast with Dale Earnhard Jr., and We’re Here To Helpwith Jake Johnson and Gareth Reynolds.

The Company is consistently reviewing additional marketing and sponsorship opportunities to further enhance brand recognition throughout the 4th quarter and beyond.

  • Global Expansion Opportunities: The Company has begun the process of identifying potential additional markets outside of the United States which it may seek to market and sell its Mango ED products in the future, with some of these markets requiring a doctor’s prescription (e.g., the United Kingdom) and others where ED products can be sold over the counter at local pharmacies (e.g., Mexico and other parts of South America). The Company’s decision to become the headline sponsor for the upcoming Raindance Film Festival in London is due to its interest in the United Kingdom as a potential viable option for global expansion.

Jacob Cohen, the Company’s Co-Founder and Chief Executive Officer stated, “We are extremely grateful to our loyal shareholders for your patience and commitment. We are fully dedicated to making Mango one of the top names in men’s health and wellness and we believe we have a strong plan to deliver on that commitment. As we approach the close of 2023, we believe we are finally beginning to see accelerating growth in brand recognition and revenues. We plan to continue to invest and reinvest in driving new customer acquisition in our flagship Mango ED products, funding permitting, while expanding into new verticals where our prior investments in the Mango brand are expected to have an established footprint with prospective customers. Stay tuned. The excitement is just beginning!”

MANGOCEUTICALS EXPANDS ITS MEN’S HEALTH PRODUCT LINE WITH COMPOUNDED HAIR GROWTH TREATMENT ‘GROW’ BY MANGORX

DALLAS, TX / ACCESSWIRE / November 16, 2023 / Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” today announced the expansion of its men’s health product line with the addition of its hair growth treatment, ‘Grow.’

The custom compounded hair growth treatment combines four clinically proven hair growth products – Minoxidil, Finasteride, Vitamin D3, and Biotin – encapsulated in convenient chewable, mint-flavored tablets. The product is now available for delivery by prescription through MangoRx’s website.

“The launch of ‘Grow’ signifies a giant step in the Company’s overall progress and mission to provide our customers with custom and innovative products and solutions under the MangoRx brand,” said Jacob Cohen, MangoRx’s co-founder and CEO. “When it comes to hair, we’re all about the upward and onward journey. Grow aligns with MangoRx’s mantra of performance, evolution, and achieving the best version of oneself. Unlike most of our competitors, we have reinforced our commitment and ongoing investment in providing oral dissolvable tablets with distinctive flavors. This ensures our customers avoid the hassle of messy topical treatments, preventing their hair from appearing wet and greasy. With Grow, it is confidence that’ll go to your head!”

Grow’s unique compounded formula combines Minoxidil, which encourages blood flow and follicle development, with Finasteride, blocking the formation of DHT (a known cause of male pattern baldness), along with supplements Vitamin D3, slowing hair-follicle calcification, and Biotin, which plays a crucial role in healthy hair growth. When combined, the four clinically proven hair growth products work to promote new growth in three to six months.

“As a healthcare provider, I offer my professional endorsement of this compounded oral dissolvable tablet as a valuable option for addressing hair loss concerns,” said Dr. Douglas Christianson, ND, advisory board member of MangoRx. “The meticulously formulated combination of Minoxidil, Finasteride, Biotin, and Vitamin D3 aligns with evidence-based approaches to hair restoration. This cutting-edge solution has demonstrated clinical efficacy in fostering hair regrowth and enhancing the overall health of the hair. It stands as a medically sound choice for individuals seeking to address hair loss.”

According to the American Hair Loss Association, by the age of 35 two-thirds of American men will experience some degree of increased hair loss, and by the age of 50, approximately 85 percent of men have significantly thinning hair. The process of male pattern baldness can begin before the age of 21 for approximately 25% percent of men.

Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

DAILY HAIR TREATMINT

GROW BY MANGORX

(4 Active Ingredients in 1)

BENEFITS:

Powerful Ingredients: Packed with Minoxidil, Finasteride, Vitamin D3, and Biotin for proven hair growth.

Regrow & Renew: Ingredients have been clinically shown to regrow hair in 3-6 months, stopping hair loss in its tracks.

Minty Freshness: Enjoy the burst of mint flavor as you chew your way to stronger hair!

Follicle Fuel: Boosts circulation to your hair roots, helping your mane thrive.

Monthly Magic: 30-day or 90-day supply to keep the good hair vibes flowing.

OUR UNIQUE FORMULA

Grow by MangoRx is a uniquely compounded pharmaceutical hair growth formula housed in a sleek tin with a 30 or 90-day supply of chewable mint-flavored tablets. Infused with power-packed ingredients, Grow is designed to target the root causes of thinning hair and promote growth.

MINOXIDIL

Boosts circulation to follicles, helping them thrive and regrow hair in just 3-6 months.

FINASTERIDE

Targets male pattern hair loss by blocking the hormone responsible for hair growth interruption.

BIOTIN

Feeds your hair by aiding in keratin production, ensuring strands are healthy, strong, and shiny.

VITAMIN D3

An essential vitamin to nurture and strengthen hair, enhancing its natural resilience.

Grow by MangoRx, a proven blend of 4 hair growth ingredients, ensures that taking the steps toward a fuller head of hair has never been easier. Mint-flavored and easy to take, Grow by MangoRx is more than a product—it’s a promise to help you reclaim the hair you love. Join the revolution and let Grow bring your hair back to life!

MANGOCEUTICALS, INC.’S DEBUT COMMERCIAL SURPASSES 9.3 MILLION VIEWS ON YOUTUBE

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

Tapping into a market of more than 40,000 pharmacies, retail outlets, and convenience stores across Mexico in 2024 and fueling International Sales Access Across Latin America

Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the establishment of its subsidiary, MangoRx Mexico, which will act as the lynchpin of the Company’s Mexican and expanded Latin American sales strategies for its Mango ED products.

The Company has engaged one of the largest international law firms, Diaz Reus International Law Firm, to establish its subsidiary presence in Mexico. With offices across five continents, Diaz Reus represents major Fortune 500 brands including Oracle, Nissan, Sony, and Allianz, to name a few.

“This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MangoRx’s Co-Founder and CEO. “First, ED medications – such as branded and generic Viagra (Sildenafil) and Cialis (Tadalafil) – are available to consumers over-the-counter in Mexico. That presents increased margin and sales volume potential for what we already produce and market here in the United States. Second, Mexico is a completely untapped market as our research indicates that we will be the only company offering an ED product in a flavored rapid-dissolve tablet (RDT).”

Next steps include establishing a manufacturing partner, applying for, and achieving certification with, the Comisión Federal para la Protección contra Riesgos Sanitarios (“COFEPRIS”), and establishing and formalizing distribution partnerships. The Company is already engaged in substantive negotiations with potential manufacturing partners, and it intends to formalize those relationships before the end of 2023.

Cohen added, “This is not a sudden shift. We have been working on this strategy since May 2023, and we are now in the final stages of cementing our lab partner for production, packaging, and fulfillment of products. We are also already in discussions with multiple potential distribution partners in Mexicowho have existing relationships with more than 40,000 pharmacies, retail outlets, and convenience stores across the country.”

In addition, achieving the COFEPRIS certification offers additional advantages for further expanding sales of MangoRx products internationally into other large and growing Latin American markets that offer ED medications as OTC products. Specifically, the COFEPRIS is recognized in the following additional countries: Columbia, Ecuador, El Salvador, Chile, Costa Rica and Panama.

MangoRx has hired market commercialization professional, Efraim (Efi) Karchmer, as President of MangoRx Mexico. Efi will be tasked with spearheading all initiatives involved in establishing the business operations of the new subsidiary. Mr. Karchmer has more than 25 years’ experience in sales, marketing, and distribution of diverse products in a multinational and multicultural environment.

According to a recent market study and analysis report conducted by Groupo Knobloch, the estimated annual market size in Mexico for ED pharmaceutical products is USD $216 million with approximately 24 million units sold annually and growing at a rate of 4% per year at an average sales price of USD $8.50 per unit.

“Adding a new and significant market segment with fundamental advantages over our core marketplace could be one of the most important and transformative strategic steps with have taken as a company,” concluded Cohen. “The path from here to full launch of Latin American sales for MangoRx products is a top priority, and we look forward to providing updates very soon.”

About MangoRx

MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED) and hair growth. Interested consumers can use MangoRx’s telemedicine platform for a smooth medical prescription that is exclusively compounded for each individual. Orders will then be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

NEWS

 PUBLISHED

6 DAYS AGO

MANGOCEUTICALS LAUNCHES MANGORX MEXICO SUBSIDIARY, PAVING THE WAY FOR OVER-THE-COUNTER RETAIL OF ERECTILE DYSFUNCTION LINE OF PRODUCTS IN LATIN AMERICA

PUBLISHED

NOV 29, 2023

MANGOCEUTICALS SELECTS TRYBE LABS AS ITS NATIONWIDE BLOOD COLLECTION AND TESTING SERVICES PROVIDER

PUBLISHED

NOV 16, 2023

MANGOCEUTICALS EXPANDS ITS MEN’S HEALTH PRODUCT LINE WITH COMPOUNDED HAIR GROWTH TREATMENT ‘GROW’ BY MANGORX

PUBLISHED

NOV 2, 2023

MANGOCEUTICALS, INC. LAUNCHES CHARITABLE INITIATIVE IN SUPPORT OF MEN’S HEALTH AWARENESS MONTH

PUBLISHED

OCT 26, 2023

MANGOCEUTICALS LAUNCHES TIKTOK INFLUENCER INITIATIVE AND BECOMES THE PRESENTING SPONSOR OF THE ONLY STANS PODCAST WITH GLENNY BALLS

PUBLISHED

OCT 19, 2023

MANGOCEUTICALS, INC. PROVIDES UPDATE TO SHAREHOLDERS ON Q3 ACHIEVEMENTS AND GUIDANCE ON YEAR END AND NEAR-TERM INITIATIVES

PUBLISHED

OCT 13, 2023

MANGOCEUTICALS ANNOUNCES TV AIR DATES FOR INTERVIEW FEATURING CEO JACOB COHEN ON BLOOMBERG TV AND FOX BUSINESS

PUBLISHED

OCT 12, 2023

MANGOCEUTICALS ANNOUNCES THE OFFICIAL LAUNCH OF MANGORX AFFILIATE MARKETING PROGRAM TO ENHANCE AND ACCELERATE TOPLINE GROWTH

PUBLISHED

SEP 14, 2023

MANGOCEUTICALS BRAND MANGORX ANNOUNCED AS RAINDANCE FILM FESTIVAL’S HEADLINE SPONSOR

PUBLISHED

SEP 7, 2023

MANGOCEUTICALS EXPANDS ITS NATIONWIDE MARKETING EFFORTS WITH A MULTIPLATFORM AUDIO POWERHOUSE ACROSS AMERICA

PUBLISHED

AUG 30, 2023

MANGOCEUTICALS LAUNCHES NEW HIGH-PRODUCTION QUALITY AD PROVIDING FRESH INSIGHT INTO ITS PROPRIETARY MANGO ERECTILE DYSFUNCTION PILL FORMULA

PUBLISHED

AUG 16, 2023

MANGOCEUTICALS LAUNCHES NEW SILDENAFIL BASED ERECTILE DYSFUNCTION PRODUCT WITH SIGNATURE MANGO FLAVOR & RAPID DISSOLVE

MANAGEMENT

Photo of Jacob Cohen

JACOB COHEN

Co-Founder and Chief Executive Officer

Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.

Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.

From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.

Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.

Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.

Photo of Jonathan Arango

JONATHAN ARANGO

Co-Founder and President

Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.

Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.

Photo of Amanda Hammer

AMANDA HAMMER

Chief Operating Officer

Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams.

Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.

Photo of Eugene M. Johnston

EUGENE M. JOHNSTON

Chief Financial Officer

Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company.

Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWELVE THOUSAND FIVE HUNDRED USD BY BULLZEYE MEDIA LLC FOR A ONE DAY MGRX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

(Nasdaq: SLNH) Profile

OUR NEW PROFILE IS:   (NASDAQ: SLNH)

THIS DATA CENTER JUGGERNAUT IS SOLVING RENEWABLE ENERGY’SBIGGEST PROBLEM ALL WHILE BENEFITING FROM THE RISE OF BITCOIN

REVENUE IN THE THIRD QUARTER INCREASED BY 176% TO $5.8 MILLION COMPARED TO $2.1 MILLION IN THE SECOND QUARTER OF 2023

SOLUNA HARNESSES THE POWER OF COMPUTING TO ACCELERATE THE RENEWABLE ENERGY FUTURE

SLNH COMPLETED A 1-25 REVERSE SPLIT BACK IN OCTOBER, KNOCKING THE FLOAT DOWN TO JUST 1.22 MILL

MILL

____________________

Hello Everyone,

Bitcoin has been on a wild ride since the start of 2023, surging by over 80% since January. The leading digital coin exploded to an 18-month peak in November.

Despite this, many experts believe that the current rally could be just the beginning and that bitcoin has the potential to go further than its previous highs.

Many digital coins have been rebounding from their lows, with investors expressing more positive sentiments. According to Standard Chartered Bank, bitcoin will reach $100,000 by the end of 2024. The next catalyst, wrote the bank’s Geoff Kendrick and team, will be the approvals of several U.S.-based spot bitcoin ETFs, which they expect “are likely to come sooner than expected.”

“We think a number of spot ETFs will now be approved in Q1-2024 for both BTC and ETH, paving the way for institutional investment,” they said.

Pull up SLNH Imm

SLNH is a leading developer of green data centers for Bitcoin mining and other intensive computing applications.

The company builds modular, scalable data centers that convert wasted renewable energy into computing power for intensive, batchable applications such as cryptocurrency mining, AI, and machine learning. This solution provides a cost-effective alternative to battery storage or transmission lines.

IT WORKS LIKE THIS:

  • →Power plants generate renewable energy.
  • →SLNH buys its excess energy.
  • →They then use that energy to power their data centers.

MAJOR CATALYSTS

  • ✓An industry first. The company’s data center solution provides a cost-effective alternative to battery storage or transmission lines, helping power plant owners sell EVERY megawatt they have. Leveraging SLNH’s team’s unique combination of energy and technology expertise, the company is the first to offer such a revenue-generating solution,giving asset owners a competitive advantage. The company’s solution is poised to be the industry standard within 3 years!
  • ✓A $120B+ market opportunity. The company’s long-term strategy is to dominate a few relatively small niche markets (digital coin mining, GPU cloud, etc.) by offering a truly zero-carbon cloud to a variety of end markets that are currently not served by data centers. Then, it will swiftly expand into broader, related markets. $9B+ Digital currencies, $5B Scientific research $50B+ Artificial intelligence and machine learning, and $60B+ Additional compute-intensive tasks.
  • ✓Bitcoin has been exploding this year. The first market SLNH is applying its strategy to is the digital currency market. And many digital coins including Bitcoin have been rebounding tremendously!
  • ✓Revenue potential. As described in the company’s earnings power illustration, the combined revenue potential for its sites: Project Dorothy 1A, Project Dorothy 1B, and Project Sophie is $37.5 million on an annualized basis!
  • ✓Strong Q3 Results. The company financial results for the third quarter ended September 30, 2023, including a 176% increase in revenue and operating profit milestone.
  • ✓A competitive edge SLNH has one of the industry’s lowest mining costs when referring to cost of revenue (mining) and all-in business costs!
  • ✓Meeting a growing need. Stronger policies and raised climate goals are driving renewables to new records. By 2026, global renewable electricity capacity is forecast to rise more than 60% from 2020 levels to over 4 800 GW – equivalent to the current total global power capacity of fossil fuels and nuclear combined
  • ✓Experienced management. SLNH has formed a new Advisory Board and the appointment of Daniel Golding, a former head of advanced engineering and data center innovation at Google. The Advisory Board has been formed to further accelerate the Company’s plan to offer its AI customers purpose-built facilities powered by renewable energy at groundbreaking costs.

THE COMPANY IS IN THE BUSINESS OF BUYING CURTAILED RENEWABLE ENERGY TO PROVIDE ENERGY-INTENSIVE COMPUTING SERVICES FOR PROFITS SUCH AS USING CURTAILED ENERGY TO MINE BITCOIN.

It’s a very straightforward business: to create an economy in the curtailed (wasted) renewable energy subsector. The company locates sites with curtailed energy (that meets its criteria) and then builds facilities around them to produce marketable products and services. (Batchable computing).

Up to 30% of the power of renewable energy projects can go to waste but Soluna’s data centers enable clean electricity asset owners to ‘Sell. Every. Megawatt!’

Soluna Holdings, Inc. (NASDAQ: SLNH) works with some of the largest plant owners in the world and brings its advanced facilities to different projects.

SLNH is building projects that absorb renewable energy and can take the projects out of their ailing positions where they don’t monetize all the energy.

The company brings in a data center solution; a computing solution, that is built on-site with the facility to absorb the wasted energy and convert it to a global resource. A low-cost, clean, green, and sustainable energy.

WHY IS THIS IMPORTANT?

SLNH is helping power plants reach their revenue goals and get more megawatts to the grid. This in turn will make renewable, affordable energy the world’s primary power source.

HOW IS THIS BEING DONE?

  • →By bringing demand to power plants. 
  • →Building mobile data centers at the location where power is generated. 
  • →And applying that energy to the growing, worldwide demand for high-intensive computing.

SLNH is a team of experts, professionals & entrepreneurs suited to bring green to power plants, grids, and the world economy.

LEADING CURTAILMENT SOLUTIONS PROVIDER TO THE RENEWABLE ENERGY BUSINESS

We buy excess energy from directly renewable power plants and convert it to clean, low-cost global computing

FOCUS ON RETURN OF INVESTED CAPITAL (ROIC) & CAPITAL DISCIPLINE

Focus on low power cost (~2.7 ¢ per kWh) and efficient CAPEX for capital deployment optimization. Design projects to return capital invested in 2 years

LONG-TERM STRATEGY BEYOND BITCOIN TO AI

The company takes excess energy from renewable energy sources and funnels it to batch-oriented, to power batch-oriented computing. Digital currency is one of them.
The company has the right plan for a volatile environment that they have specifically engineered to thrive even in a digital coin downturn.

A GROWING PIPELINE OF PROJECTS…

The company’s data centers can buy every excess megawatt to use for batch-oriented, computing-intensive processes such as digital currency mining or machine learning, and this solution is as low-risk and low-friction to use as a smartphone.

PROJECTS INCLUDE:

PROJECT DOROTHY 1A AND 1B – TEXAS (FLAGSHIP SITE)

SLNH has now monetized a groundbreaking 1,286 MWh of curtailed (wasted) energy for its Power Partner at Project Dorothy. This is equivalent to driving an electric car for more than 4.8 million miles (assuming 3 miles per kWh).

Soluna Bolsters Revenue Potential with Purchase of More than 8,250 Machines to Power Project Dorothy 1B!

The 25 MW Project Dorothy 1B is a proprietary mining joint venture between Soluna and Navitas Global. The first 5 buildings, which is approximately 6 MW, were set to be energized by the end of June. The remainder is expected to be completed and energized in the third quarter. The site’s run-rate revenue from mining is approximately $18 million annually.

Once Project Dorothy 1B is operational, the 50 MW Project Dorothy Phase 1 will be fully online with a mix of hosting and proprietary mining.

PROJECT SOPHIE

  • →On April 6, 2023 Soluna announced a 25 MW hosting contract with a sustainability focused hosting customer.
  • →Since then, Soluna has deployed miners to the entire site and has been running at full capacity.
  • →In June, the site achieved one of the highest utilization in its operating history
  • →The site holds great revenue potential, estimated at $3.21 million on an annualized basis. (As of Earnings Power Illustration June 21, 2023.)
  • →Hosting diversification – New hosting customers have been signed and deployed at Project Sophie. Three new hosting contracts have been signed and deployed since September.

PROJECT KATIE

  • →Project Kati continues the development process, completing the first of the three required ERCOT interconnection studies in the planning phase. It has also advanced legal agreements with its power partner.

DIVERSIFYING REVENUE STREAMS

SLNH HAS COMPLETED ITS REGISTRATION FOR ANCILLARY SERVICES TO DIVERSIFY ITS REVENUE STREAMS.

Ancillary Services Adds More Revenue and Lowers Power Cost – Soluna registered for ERCOT’s Demand Response Program establishing the company as a key contributor to intelligent and flexible energy solutions, promoting environmental and economic advantages for Texas.

Soluna will be able to make over $10/MWh in additional revenue to Project Dorothy providing this grid resilience support and potentially reduce its power costs below $20/MWh, making it among the lowest cost players in the industry!

THE AI EDGE…

SLNH has launched Helix, an initiative to design an upgrade to its existing data center to address the needs of AI training workloads.

The company believes the overwhelming unmet demand for power and computing space in the AI field will allow Soluna to transform its super low cost computing infrastructure to meet AI’s exponentially growing needs.

Soluna’s data centers and proprietary MaestroOS software have been designed for this opportunity since inception. As Soluna converts its asset base to be AI-centric, it expects to offer its AI customers purpose-built facilities powered by renewable energy at groundbreaking costs.

SLNH HAS ALREADY ACHIEVED RECORD LOW POWER COSTS PAVING THE WAY FOR AI COMPUTING AT PROJECT DOROTHY!

And bringing on Daniel Golding’s expertise with more than 30 years of experience at companies like Google and Iron Mountain will accelerate Helix!

The continual challenge in AI will be access to power, sustainability, physical space and compute availability. Soluna with its Helix program is on the path to solve this, and Daniel’s expertise will accelerate this mission. He will provide valuable advice to the Management Team and Board of Directors as the company steers the ship to phase two of its strategic business plan.

SLNH expects to add more of the brightest minds in AI, data center development, and renewable energy to its Advisory Board in the coming months.

The transformation of the global economy needed to achieve net-zero emissions by 2050 would be universal and significant.

There’s a good reason why green stocks, or clean energy stocks, are some of the smartest choices for any portfolio going forward. The space is not only helping to preserve the environment and create new industries but also may make electric cars more affordable.

Renewable energy sources such as wind, solar, and hydroelectric power are expected to play a big part in our future. While renewable energy is a big topic, curtailment is a very big problem that is little talked about and one that could create many problems down the road….

By building infrastructure to help renewable energy become a ‘superpower,’ Soluna Holdings, Inc. (NASDAQ: SLNH) has a game-changing solution to curtailment.

THE COMPANY’S SCALABLE DATA CENTERS TURN WASTED ENERGY INTO REVENUE WITHIN 6 MONTHS!

SLNH is also a green data center crypto mining company and despite the headlines buzzing around companies like Marathon Digital and Riot Platforms, SLNH is an undetected player with substantial room for growth.

But to give an idea of just how well the arena is doing, Marathon Digital has gained nearly 400% in 2023 and Riot Platforms is up nearly 200% in the past 12 months!

NEWS

PUBLISHED

NOV 29, 2023

SOLUNA JUMPSTARTS ANCILLARY SERVICES REVENUE

PUBLISHED

NOV 28, 2023

SOLUNA TO PRESENT AT WATER TOWER RESEARCH’S HYBRID US CLIMATE INVESTOR CONFERENCE ON DECEMBER 7

PUBLISHED

NOV 22, 2023

SOLUNA SIGNS AGREEMENT WITH NOTEHOLDERS TO FACILITATE EARLY PAYOFF OF CONVERTIBLE NOTES

PUBLISHED

NOV 15, 2023

SOLUNA HOLDINGS REPORTS Q3 RESULTS

PUBLISHED

NOV 6, 2023

SOLUNA ESTABLISHES ADVISORY BOARD, TAPS AI AND DATA CENTER LEADERSHIP

PUBLISHED

OCT 31, 2023

SOLUNA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

PUBLISHED

OCT 25, 2023

SOLUNA AND BIT DIGITAL ANNOUNCE YEAR-LONG HOSTING PARTNERSHIP

PUBLISHED

OCT 24, 2023

SOLUNA ACHIEVES RECORD LOW POWER COSTS PAVING THE WAY FOR AI COMPUTING AT PROJECT DOROTHY

PUBLISHED

OCT 13, 2023

SOLUNA ANNOUNCES IMPLEMENTATION OF 1-FOR-25 REVERSE STOCK SPLIT

PUBLISHED

OCT 12, 2023

SOLUNA ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT

PUBLISHED

OCT 5, 2023

SOLUNA TO PARTICIPATE IN WATER TOWER RESEARCH FIRESIDE CHAT SERIES

PUBLISHED

SEP 26, 2023

SOLUNA PROJECT DOROTHY 1 REACHES FULL CAPACITY OF 50 MW, COMPANY HITS 2.6 EH/S HASHRATE MILESTONE

PUBLISHED

AUG 14, 2023

SOLUNA HOLDINGS REPORTS Q2 RESULTS

PUBLISHED

JUL 25, 2023

SOLUNA HITS NEW HEIGHTS: APPROACHES 2 EH/S MILESTONE IN BITCOIN MINING OPERATIONS

PUBLISHED

JUL 18, 2023

SOLUNA TO PARTICIPATE IN WATER TOWER RESEARCH FIRESIDE CHAT SERIES

PUBLISHED

JUN 26, 2023

SOLUNA SECURES NASDAQ’S APPROVAL FOR 180-DAY EXTENSION TO MEET BID PRICE REQUIREMENT

MANAGEMENT TEAM

John Belizaire

John Belizaire

Chief Executive Officer

David Michaels

Chief Financial Officer
Soluna Holdings, Inc.

Jessica Thomas

Chief Accounting Officer
Soluna Holdings, Inc.

Dipul Patel

Dipul Patel

Chief Technology Officer
Soluna Computing, Inc.

Mary O’Reilly

Mary O’Reilly

Chief People Officer
Soluna Computing, Inc.

Larbi Loudiyi

VP, Power
Soluna Computing, Inc.

Phillip Ng

Phillip Ng

VP, Corporate Development
Soluna Computing, Inc.

Nick Lancaster

VP, Engineering
Soluna Computing, Inc.

Chase Stowell

Sr. Business Unit Controller
Soluna Computing, Inc.

Jim Reynolds

Sr. Director, Operations
Soluna Computing, Inc.

SINCERELY,

DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY SLNH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Categories
Report

(Nasdaq: ANIX) Profile

Anixa Biosciences, Inc.

OUR NEW PROFILE IS:   (NASDAQ: ANIX)

ANIX HAS TWO VACCINES AIMED TO PREVENT BREAST CANCER AND OVARIAN CANCER

ANIX HAD $23 MILLION IN CASH AS OF JULY 2023

CHECK OUT THE INVESTOR PRESENTATION HERE

https://www.youtube.com/watch?v=gIHCXB_LDwI

____________________

Hello Everyone,

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors around.

As devastating as cancer is, it’s also a big business. And when cancer and Wall Street collide, it can lead to substantial opportunities to capitalize. It’s no wonder investors are turning their eyes toward healthcare companies specializing in oncology

Precedence Research projects that the global oncology market will increase at a compound annual growth rate of 8.2 percent to reach US$581.25 billion in 2030.

Players in the oncology sector are thriving. Biotech stocks experienced a lift in early December after it was learned that AbbVie will be buying cancer developer ImmunoGen for $10 billion!

Scientific advances are creating new and previously only imaginable ways to treat and prevent diseases.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology.

Pull up ANIX immediately and start your research on the company.

The company’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.

Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.

The Company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple-negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.

These vaccine technologies focus on immunizing against “retired” proteins that are expressed in certain forms of cancer.

THE CAR-T METHOD:

The exciting field known as immunotherapy has enabled the development of drugs that modulate the immune system to battle cancer.We know that our bodies, through the function of our immune systems, are able to “cure” cancer. It is now known that some number of cells in our bodies are becoming cancerous all the time. These transformations are driven by many factors including genetics and environment.

Most of the time without us being consciously aware, these cells are destroyed and cleared by our immune system. As our immune function declines with age, some cells are able to survive and eventually become tumors, either liquid or solid. We also know that the tumors themselves have developed mechanisms to suppress immune cell function. Such is the case with pediatric tumors as well adult cancers.

Considering this understanding, the field of immunotherapy tries to boost the ability of our immune cells to battle the cancer. There are a number of methods that scientists have devised to induce our immune systems to battle cancer. One of those approaches is known a Chimeric Antigen Receptor T-cell technology, better known by the acronym, CAR-T.

CAR-T therapy is a treatment where a patient’s T-cells, a type of immune cell, are removed from the body. These cells are then modified in a laboratory through the advanced techniques of genetic engineering, and increased in number, and then infused back into the patient. In many ways, this is the ultimate personalized medicine. The specific genetic engineering is what makes the patient’s own T-cells even more powerful as a tumor fighter. This genetic engineering causes a special receptor to be present on the surface of the T-cell. This receptor is known as the CAR—the Chimeric Antigen Receptor.

The pharmaceutical industry continues to be a hotbed of innovation and CAR-T cell-based compositions are a key innovation area in immuno-oncology!

CAR-T THERAPY FOR OVARIAN CANCER:

The markets for solid tumors are much larger than the markets for leukemias and lymphomas, especially B-cell cancers. Therefore, ANIXfeels that the scope of opportunities for its CAR- T therapy is very large should the company demonstrate efficacy in solid tumors.

ANIX’S FIRST INDICATION WILL BE OVARIAN CANCER, FOLLOWED BY OTHER TUMOR TYPES.

  • ↪Ovarian cancer is the sixth most common cancer in the world, and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches.
  • ↪Late-stage diagnosis results in relatively high risks of recurrence and often poor prognosis. While the five-year survival rate for stage 1 ovarian cancer is over 80%, the corresponding survival rate for Stage 4 cancer is 20%. Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.

THE FIRST POTENTIAL ANTI-ANGIOGENIC CAR-T THERAPY:

ANIX has an exclusive worldwide license from The Wistar Institute.

The company believes its CER-T approach will work in solid tumors, especially ovarian cancer, where others have failed.

  • ↪FSHR is a unique target
  • ↪FSH is a natural ligand (not synthetic)
  • ↪The company’s approach may provide anti-angiogenic synergy
  • ↪The company’s CAR-T may execute a dual mechanism of action in destroying the tumor

PREVIOUS CHALLENGES:

  • ↪The CAR-T cells may not br susceptible to the highly suppressive tumor microenvironment
  • ↪As the CAR-T cells are destroying vasculature, they make it leakier, enabling simultaneous, localized delivery of oher agents including chemotherapy
  • ↪CAR-T mediated cell death may be more powerful than ther anti-angiogensis drugs

COLLABORATORS INCLUDE:

MOFFITT CANCER CENTER:

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999.

THE WISTAR INSTITUTE CANCER CENTER:

Founded in 1892 as the nation’s first independent biomedical research institute and located on the campus of the University of Pennsylvania, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI’s select network of national cancer research centers, holding an ‘Exceptional’ rating — the highest possible ranking awarded.

CANCER VACCINES:

Vaccines harness the immune system to keep people safe from infectious diseases. Thanks to broad-based vaccination programs, some of the most terrifying diseases in history, small pox and polio among them, have been eliminated from existence.

Unfortunately, there’s been little success in developing a preventative (prophylactic) vaccine against cancer.

Most vaccines attack pathogens, such as viruses and bacteria. The immune system is better able to assail these agents because they come from outside the body. Cancer, however, is a different matter. The disease is caused by aberrant cells that arise out of our resident cells. That can make it difficult for our immune system to find the diseased cells, especially as advancing age weakens our immune system. Once these aberrant cells gain critical mass, they become cancer.

Despite the lack of success with cancer vaccines, recently gained knowledge about the human immune system has led to the development, approval and commercialization of revolutionary immuno-therapy drugs. These drugs do not attack cancer directly, but rather modulate the immune system in ways that enable it to destroy or dramatically impair cancer cells.

Imagine if we could train the immune system to kill cancer cells as they arise before they form into tumors. Perhaps, we could eliminate the onset of cancer. The difficulty has been to identify an agent that allows the immune system to target malignant cells without harming healthy tissue.

  • ↪Cleveland Clinic researchers have identified a protein called alpha-lactalbumin that is present in healthy breast tissue only when a woman is lactating and disappears when she stops nursing her child. Alpha-lactalbumin is never present on any other cell in the body. However, it does show up in many types of breast cancer, including an aggressive and deadly form of the disease known as Triple Negative Breast Cancer (TNBC).
  • ↪In addition, Cleveland Clinic researchers have identified that the extracellular domain of anti-Mullerian hormone receptor II (AMHR2-ED) is expressed in normal ovaries, and nowhere else in the body, with this expression ceasing after menopause. However, this protein is also expressed in cancerous ovary cells.
  • ↪Cleveland Clinic, has received an “Intention to Grant” notice from the European Patent Office (“EPO”) for the patent application titled “Ovarian Cancer Vaccines.”

BY DEVELOPING VACCINES THAT TARGET ALPHA-LACTALBUMIN AND AMHR2-ED, ANIX FEELS THE IMMUNE SYSTEM CAN DESTROY BREAST CANCER CELLS AND OVARIAN CANCER CELLS, RESPECTIVELY, AS THEY ARISE AND ULTIMATELY PREVENT TUMORS FROM FORMING!

Anixa’s ovarian cancer vaccine targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.

THE MARKET FOR PROPHYLACTIC CANCER VACCINES IS SIZABLE, BIGGER IN FACT THAN THE MARKET FOR ANY TYPE OF CANCER THERAPEUTIC. AFTER ALL, DOCTORS ADMINISTER CANCER DRUGS ONLY AFTER A PATIENT HAS BEEN DIAGNOSED, WHILE A VACCINE CAN BE ADMINISTERED TO A FAR WIDER POPULATION.

BREAST CANCER:

In the U.S., nearly 300,000 women are expected to be diagnosed with breast cancer this year.

OVARIAN CANCER:

Ovarian cancer is the sixth most common cancer in the world, and one of the most aggressive reproductive cancers among women. Most ovarian cancers are diagnosed at late stages (stage 3 or 4) due to the typical absence of symptoms and lack of screening approaches. Worldwide, over 200,000 cases of ovarian cancer are diagnosed annually.

PHASE 1 TRIAL FOR BREAST CANCER VACCINE: CONDUCTED BY CLEVELAND CLINIC, FUNDED BY U.S. DEPARTMENT OF DEFENSE (DOD)

AN OPEN-LABEL PHASE 1 DOSE-ESCALATION TRIAL

DESIGN

Participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response

PHASE 1A
(IN PROGRESS)

  • ↪18-24 Patients who have been treated for TNBC
  • ↪Safety will be monitored
  • ↪Immune Response will be monitored
  • ↪Maximum Tolerated Dose (“MTD”) determined

PHASE 1B
(ENROLLMENT OPEN)

  • ↪Healthy women w/mutations
  • ↪Chosen to undergo prophylactic mastectomy
  • ↪Vaccinate before surgery and evaluate immune response and resected tissue
  • ↪Unique opportunity to garner supplemental data after studying breast tissue to determine if T cells are surveilling the tissue without any visible cancer tumors

PHASE 1C
(ENROLLMENT OPEN)

  • ↪Additional cohort combining vaccine with Keytruda
  • ↪Patients treated for TNBC
  • ↪Combine Keytruda w/ vaccine to evaluate if there is synergy

POSITIVE CLINICAL RESULTS AS OF APRIL 2023:

  • ↪Enrollment of women who have had TNBC and have undergone standard of care, but are at risk of recurrence
  • ↪42% of TNBC survivors will relapse within 5 years
  • ↪MTD reached in Q4 2022 § Data from all vaccinated women tested to date presented at AACR in April 2023
  • ↪16 patients dosed through July 2023
  • ↪No safety concerns
  • ↪Immune responses observed at all dose levels
  • ↪All patients had some immune response
  • ↪Intensity of responses varied with patients

IN SUMMARY…

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells.The goal to prevent the disease or eradicate it has been monumental in big pharma for decades.

With multiple catalysts over the next 12 months across its clinical pipeline, now is a pivotal time to have Anixa Biosciences, Inc. (NASDAQ: ANIX) on your radar. The company has 2 clinical trials in progress, showing positive results!

ANIX highlights:

  • ↪$25M+ in cash as of July 2023
  • ↪A low-cost business model
  • ↪Developing programs with partners
  • ↪Leveraging existing infrastructure of partners
  • ↪Maintaining low overhead and cash burn
  • ↪Potential to out-license programs to pharma for late stage clinical development and commercialization

NEWS

ANIXA BIOSCIENCES ANNOUNCES EUROPEAN PATENT ON OVARIAN CANCER VACCINE TECHNOLOGY

NOVEMBER 27, 2023

ANIXA BIOSCIENCES TO PRESENT AT THE OVARIAN CANCER RESEARCH ALLIANCE (OCRA) OVARIAN CANCER NATIONAL CONFERENCE

OCTOBER 31, 2023

ANIXA BIOSCIENCES APPOINTS ACCOMPLISHED MEDICAL ONCOLOGIST AND BIOTECHNOLOGY EXECUTIVE, DR. MARK A. GOLDBERG, TO CANCER BUSINESS ADVISORY BOARD

OCTOBER 23, 2023

ANIXA BIOSCIENCES COMPLETES TREATMENT OF FIRST PATIENT COHORT IN OVARIAN CANCER CAR-T CLINICAL TRIAL

OCTOBER 13, 2023

ANIXA BIOSCIENCES ANNOUNCES ISSUANCE OF ADDITIONAL U.S. PATENT FOR OVARIAN CANCER VACCINE TECHNOLOGY

OCTOBER 3, 2023

ANIXA BIOSCIENCES ESTABLISHES CANCER BUSINESS ADVISORY BOARD

SEPTEMBER 19, 2023

ANIXA BIOSCIENCES TO PARTICIPATE IN SEPTEMBER INVESTOR CONFERENCES

AUGUST 31, 2023

ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF THIRD PATIENT IN OVARIAN CANCER CAR-T CLINICAL TRIAL

AUGUST 28, 2023

ANIXA BIOSCIENCES ANNOUNCES INVITED PRESENTATION ON OVARIAN CANCER CAR-T THERAPY AT THE 8TH ANNUAL CAR-TCR SUMMIT

AUGUST 14, 2023

COULD ANIXA BIOSCIENCES (NASDAQ:ANIX) BE DEVELOPING THE VACCINE TO END ONE OF THE DEADLIEST TYPES OF BREAST CANCER?

AUGUST 10, 2023

ANIXA BIOSCIENCES ANNOUNCES OPENING OF ENROLLMENT FOR KEYTRUDA® ARM IN ONGOING BREAST CANCER VACCINE CLINICAL TRIAL

AUGUST 7, 2023

ANIXA BIOSCIENCES ANNOUNCES NOTICE OF ALLOWANCE OF ADDITIONAL PATENT ON OVARIAN CANCER VACCINE TECHNOLOGY

JULY 27, 2023

ANIXA BIOSCIENCES ANNOUNCES ISSUANCE OF CANADIAN PATENT FOR ITS CAR-T CANCER THERAPY TECHNOLOGY

JULY 11, 2023

ANIXA BIOSCIENCES ANNOUNCES TREATMENT OF SECOND PATIENT IN ITS OVARIAN CANCER CAR-T CLINICAL TRIAL

MAY 22, 2023

ANIXA BIOSCIENCES CLARIFIES POSTER PRESENTATION ON COMPANY WEBSITE

APRIL 17, 2023

ANIXA BIOSCIENCES AND CLEVELAND CLINIC PRESENT POSITIVE DATA FOR PHASE 1 STUDY OF BREAST CANCER VACCINE

APRIL 17, 2023

ANIXA BIOSCIENCES ANNOUNCES PRESENTATION ON BREAST CANCER VACCINE TRIAL AT THE 2023 AACR ANNUAL MEETING

MARCH 27, 2023

ANIXA BIOSCIENCES REASSURES SHAREHOLDERS IT HAS NO ACCOUNTS AT SILICON VALLEY BANK

MARCH 13, 2023

ANIXA BIOSCIENCES TO PROVIDE CORPORATE UPDATE AT ITS 2023 ANNUAL MEETING OF STOCKHOLDERS

MARCH 2, 2023

ANIXA BIOSCIENCES ANNOUNCES NOTICE OF ALLOWANCE OF ADDITIONAL KEY PATENT ON BREAST CANCER VACCINE TECHNOLOGY

FEBRUARY 27, 2023

MANAGEMENT TEAM

Amit Kumar, Ph.D.

AMIT KUMAR, PH.D.

Chairman & Chief Executive OfficerDr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

Michael Catelani

MICHAEL CATELANI

President, COO & CFOMr. Catelani is a seasoned executive with over 30 years of finance and operations management experience. He currently serves as President, Chief Operation Officer & Chief Financial Officer of Anixa Biosciences. Previously, Mike cofounded Tacere Therapeutics, Inc., a privately held biotech company, and served as its Chairman, President & Chief Financial Officer until its sale. Prior to Tacere, Mike served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotech company. Mike was Vice President and Chief Financial Officer at Axon Instruments, a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Axon was a U.S. corporation publicly traded on the Australian Stock Exchange. Previously, he was the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mike has also worked with several early-stage start-ups in a variety of industries, including biotechnology, cleantech  and retail, in both advisory and management roles and has served as a contract CFO for a number of established businesses in the biotech field. Mike began his professional career at Ernst & Young and is a CPA (Inactive). He received his BS degree in business administration, with a concentration in accountancy from Sacramento State University and earned his MBA from the University of California, Davis.

Pamela D. Garzone, Ph.D.

PAMELA D. GARZONE, PH.D.

Chief Development OfficerDr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech. Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. She earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh. She received her Ph.D. in Clinical Science from the University of Pittsburgh.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY SICA MEDIA LLC FOR A ONE DAY ANIX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.